I'll share an email I just sent off to Biota, for what it is worth. And for those who believe I am wasting PC's time in sending him an email, put me on ignore and then you won't benefit from gleaning any of the feedback I might receive and post (BTW, my last email to him was a complaint about the last Press Release):
"Peter
The Biota die hards are hard to find these days.
Is there any info you can release to the market to ignite some interest in Biota? I?m sure that in a company with as much going on as Biota, there is scope for an update.
How about an update on Relenza and US Stockpiling? I understand that GSK does the selling, but surely you have an opinion you can share with the market on some anticipated action on US Stockpile orders.
I understand you have a totally different view of PR than me and many Biota investors, but surely it wouldn?t take too much effort to provide an update to the market. Mesoblast, particularly and Acrux both appear to embrace the concept?"
BTA Price at posting:
96.0¢ Sentiment: LT Buy Disclosure: Held
